Shaun R Stauffer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9586297/publications.pdf

Version: 2024-02-01

24 papers 950 citations

759233 12 h-index 610901 24 g-index

25 all docs

25 docs citations

25 times ranked 1764 citing authors

#	Article	IF	Citations
1	Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CL ^{pro}). Journal of Medicinal Chemistry, 2022, 65, 2880-2904.	6.4	78
2	Aminopyridine analogs selectively target metastatic pancreatic cancer. Oncogene, 2022, 41, 1518-1525.	5.9	2
3	Platelet olfactory receptor activation limits platelet reactivity and growth of aortic aneurysms. Journal of Clinical Investigation, 2022, 132, .	8.2	18
4	Peripheral sTREM2-Related Inflammatory Activity Alterations in Early-Stage Alzheimer's Disease. Journal of Immunology, 2022, 208, 2283-2299.	0.8	2
5	The discovery of VU0486846: steep SAR from a series of M1 PAMs based on a novel benzomorpholine core. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2175-2179.	2.2	10
6	Contributions of Protease-Activated Receptors PAR1 and PAR4 to Thrombin-Induced GPIIbIIIa Activation in Human Platelets. Molecular Pharmacology, 2017, 91, 39-47.	2.3	29
7	Further optimization of the M1 PAM VU0453595: Discovery of novel heterobicyclic core motifs with improved CNS penetration. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3822-3825.	2.2	11
8	mGlu ₅ positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome. Human Molecular Genetics, 2016, 25, 1990-2004.	2.9	48
9	Preliminary investigation of $6,7$ -dihydropyrazolo[$1,5$ - a]pyrazin-4-one derivatives as a novel series of mGlu 5 receptor positive allosteric modulators with efficacy in preclinical models of schizophrenia. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 429-434.	2.2	7
10	Discovery of Small-Molecule Nonfluorescent Inhibitors of Fluorogen–Fluorogen Activating Protein Binding Pair. Journal of Biomolecular Screening, 2016, 21, 74-87.	2.6	2
11	Discovery of VU0409551/JNJ-46778212: An mGlu ₅ Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia. ACS Medicinal Chemistry Letters, 2015, 6, 716-720.	2.8	41
12	Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes. Cell, 2015, 161, 1252-1265.	28.9	135
13	Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5). Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1310-1317.	2.2	9
14	Relationship between In Vivo Receptor Occupancy and Efficacy of Metabotropic Glutamate Receptor Subtype 5 Allosteric Modulators with Different In Vitro Binding Profiles. Neuropsychopharmacology, 2015, 40, 755-765.	5.4	40
15	Further optimization of the mGlu5 PAM clinical candidate VU0409551/JNJ-46778212: Progress and challenges towards a back-up compound. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3515-3519.	2.2	7
16	Targeting zoonotic viruses: Structure-based inhibition of the 3C-like protease from bat coronavirus $HKU4ae^{9}$ The likely reservoir host to the human coronavirus that causes Middle East Respiratory Syndrome (MERS). Bioorganic and Medicinal Chemistry, 2015, 23, 6036-6048.	3.0	65
17	Chemical inhibition of fatty acid absorption and cellular uptake limits lipotoxic cell death. Biochemical Pharmacology, 2015, 98, 167-181.	4.4	43
18	Acyl dihydropyrazolo[1,5-a]pyrimidinones as metabotropic glutamate receptor 5 positive allosteric modulators. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5115-5120.	2.2	5

#	Article	IF	CITATION
19	Discovery and SAR of muscarinic receptor subtype 1 (M1) allosteric activators from a molecular libraries high throughput screen. Part 1: 2,5-Dibenzyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-ones as positive allosteric modulators. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 384-388.	2.2	9
20	Discovery and SAR of a novel series of metabotropic glutamate receptor 5 positive allosteric modulators with high ligand efficiency. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3641-3646.	2.2	7
21	Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists: Discovery and SAR of ML354. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4708-4713.	2.2	35
22	respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: Identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6172-6177.	2.2	113
23	Discovery, Synthesis, And Structure-Based Optimization of a Series of <i>N</i> -(<i>tert</i> -(i)-Butyl)-2-(<i>N</i> -(i)-arylamido)-2-(pyridin-3-yl) Acetamides (ML188) as Potent Noncovalent Small Molecule Inhibitors of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease, Journal of Medicinal Chemistry, 2013, 56, 534-546.	6.4	178
24	Progress toward Positive Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 5 (mGlu ₅). ACS Chemical Neuroscience, 2011, 2, 450-470.	3.5	56